Tags

Type your tag names separated by a space and hit enter

Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone.
Acta Ophthalmol. 2009 Aug; 87(5):498-500.AO

Abstract

PURPOSE

We aimed to investigate associations between serum levels of the advanced glycation endproduct methylglyoxal-derived hydroimidazolone (MG-H1) and retinopathy in a sample of patients with type 1 diabetes.

METHODS

We conducted a cross-sectional study in a Scandinavian ophthalmology outpatient clinic on 61 randomly selected patients with type 1 diabetes. Blood samples and retinal photographs were taken at the same visit. Serum levels of hydroimidazolone immunoreactivity were determined using an immunoassay, and levels of retinopathy were determined from seven standard field stereo photographs of each eye according to the ETDRS method. Results were compared between patients with and without retinopathy.

RESULTS

Hydroimidazolone quartiles were significantly associated with retinopathy (p = 0.013). The most profound increase in occurrence of retinopathy was observed from the lowest to the second-lowest hydroimidazolone quartile. Adjusted for duration of diabetes using logistic regression, a significant difference in the presence of retinopathy was found when comparing the lowest quartile with the rest (p = 0.022).

CONCLUSIONS

In our patients with type 1 diabetes, serum levels of hydroimidazolone were found to be associated with retinopathy. This is in keeping with findings in a larger sample of patients with type 2 diabetes.

Authors+Show Affiliations

Diabetes Research Centre, Aker and Ullevål University Hospitals, Oslo, Norway. dag.fosmark@medisin.uio.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18631328

Citation

Fosmark, Dag S., et al. "Increased Retinopathy Occurrence in Type 1 Diabetes Patients With Increased Serum Levels of the Advanced Glycation Endproduct Hydroimidazolone." Acta Ophthalmologica, vol. 87, no. 5, 2009, pp. 498-500.
Fosmark DS, Berg JP, Jensen AB, et al. Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone. Acta Ophthalmol. 2009;87(5):498-500.
Fosmark, D. S., Berg, J. P., Jensen, A. B., Sandvik, L., Agardh, E., Agardh, C. D., & Hanssen, K. F. (2009). Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone. Acta Ophthalmologica, 87(5), 498-500. https://doi.org/10.1111/j.1755-3768.2008.01300.x
Fosmark DS, et al. Increased Retinopathy Occurrence in Type 1 Diabetes Patients With Increased Serum Levels of the Advanced Glycation Endproduct Hydroimidazolone. Acta Ophthalmol. 2009;87(5):498-500. PubMed PMID: 18631328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone. AU - Fosmark,Dag S, AU - Berg,Jens P, AU - Jensen,Aase-Brith, AU - Sandvik,Leiv, AU - Agardh,Elisabet, AU - Agardh,Carl-David, AU - Hanssen,Kristian F, Y1 - 2008/07/09/ PY - 2008/7/18/pubmed PY - 2009/11/7/medline PY - 2008/7/18/entrez SP - 498 EP - 500 JF - Acta ophthalmologica JO - Acta Ophthalmol VL - 87 IS - 5 N2 - PURPOSE: We aimed to investigate associations between serum levels of the advanced glycation endproduct methylglyoxal-derived hydroimidazolone (MG-H1) and retinopathy in a sample of patients with type 1 diabetes. METHODS: We conducted a cross-sectional study in a Scandinavian ophthalmology outpatient clinic on 61 randomly selected patients with type 1 diabetes. Blood samples and retinal photographs were taken at the same visit. Serum levels of hydroimidazolone immunoreactivity were determined using an immunoassay, and levels of retinopathy were determined from seven standard field stereo photographs of each eye according to the ETDRS method. Results were compared between patients with and without retinopathy. RESULTS: Hydroimidazolone quartiles were significantly associated with retinopathy (p = 0.013). The most profound increase in occurrence of retinopathy was observed from the lowest to the second-lowest hydroimidazolone quartile. Adjusted for duration of diabetes using logistic regression, a significant difference in the presence of retinopathy was found when comparing the lowest quartile with the rest (p = 0.022). CONCLUSIONS: In our patients with type 1 diabetes, serum levels of hydroimidazolone were found to be associated with retinopathy. This is in keeping with findings in a larger sample of patients with type 2 diabetes. SN - 1755-3768 UR - https://www.unboundmedicine.com/medline/citation/18631328/Increased_retinopathy_occurrence_in_type_1_diabetes_patients_with_increased_serum_levels_of_the_advanced_glycation_endproduct_hydroimidazolone_ L2 - https://doi.org/10.1111/j.1755-3768.2008.01300.x DB - PRIME DP - Unbound Medicine ER -